Among initiators of GLP1 receptor agonists versus SGLT2 inhibitors, the direction of effect modification by age in two prior studies [16, 25] was conflicting, and the direction of effect modification by cardiovascular disease and sex in our study disputes prior evidence [16, 25]
Diabetes Care 15:dc202887 Hiruma S, Shigiyama F, Hisatake S, Mizumura S, Shiraga N, Hori M, Ikeda T, Hirose T, Kumashiro N (2021) A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study
Pure Potency Provides l-carnitine in its most bioavailable form
From Venom to Blockbuster Drugs The lizard did not directly give the world semaglutide